Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
Julien PoupartJonathan GiovannelliRomain DeschampsBertrand AudoinJonathan CironElisabeth MaillartCaroline PapeixNicolas CollonguesBertrand BourreMickael CohenSandrine WiertlewskiOlivier OutteryckDavid LaplaudSandra VukusicRomain MarignierHelene Zephirnull nullPublished in: Neurology (2020)
That study provides Class III evidence that for patients with NMOSD, first-line RTX is superior to MMF to reduce the risk of relapse.
Keyphrases